Pericardial effusion (except trace effusion identified by echocardiogram) within three months prior to randomization
No history of the following:\r\n* Class III or IV congestive heart failure (CHF)\r\n* Grade  or  thromboembolic event =<  months\r\n* Pericardial effusion =<  months (any grade)\r\n* Pericardial involvement with tumor\r\n* Grade  or higher pleural effusion =<  months
Patients must not have active pericardial effusion, ascites or pleural effusion of any grade based on chest x-ray and echocardiogram within  days prior to registration; exception: if the effusion is suspected to be related to the leukemia, the patient may have pericardial effusion =< grade  or pleural effusion =< grade 
Uncontrolled pleural effusion, pericardial effusion, or ascites
Cardiac ejection fraction >= %, no evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings
Presence of fluid collection (ascites, pleural, or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated.
Pleural or pericardial effusions of any grade at study entry; subjects previously diagnosed with pleural/pericardial effusion of any grade resolved at the time of study entry are allowed
Myocardial infarction within  months prior to screening, or pericardial effusion,
Pleural or pericardial effusion\r\n* A patient with pleural effusion may be enrolled the effusion is sampled by thoracentesis and cytology is negative or the effusion is seen on axial imaging but not on chest x-ray and deemed too small to tap under CT or ultrasound guidance
Concurrent medical condition that would increase drug toxicity: pleural or pericardial effusion, coagulation or platelet function disorder, ongoing or recent (less than  months gastrointestinal bleeding)
Presence of medically significant third space fluid (symptomatic pericardial effusion, ascites or pleural effusion requiring repetitive paracentesis)
Current, or history of a pericardial effusion, and/or hemodynamic compromise due to pericardial effusion of any size; minimal pericardial effusion <  cc is not excluded
Cardiac ejection fraction ? %, no evidence of pericardial effusion, and no clinically significant arrhythmias
Cardiac arrhythmia not controlled with medical management, evidence of pericardial effusion on imaging that is compromising function
Cardiac ejection fraction >= %, no evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings
Ascites or pericardial effusion that required intervention within  months prior to study treatment
Patients with known extrathoracic metastases, including brain metastases, or known malignant pleural or pericardial effusion
Normal cardiac ejection fraction (greater than or equal to % by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within  weeks of the start of the treatment protocol
Cardiac ejection fraction ? %, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings
DASATINIB\r\n* Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)\r\n* Known pulmonary arterial hypertension\r\n* Patients may not have clinically significant pleural or pericardial effusion per provider discretion
No pleural or pericardial effusion of any grade
Normal cardiac ejection fraction (greater than or equal to % by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within  weeks of the start of the treatment protocol
Patients with evidence of a malignant pleural or pericardial effusion
Patients with any amount of clinically significant pericardial effusion
Pleural/pericardial effusion or ascites >  L
Dasatinib \r\n* Known pulmonary arterial hypertension\r\n* Patients may not have pleural or pericardial effusion of any grade\r\n* Patients may not have clinically significant pleural or pericardial effusion per provider discretion\r\n* Uncontrolled hypertension: inability to maintain blood pressure below the limit of / mgHg\r\n* Any history of second or third degree heart block (may be eligible of the subject currently has a pacemaker)
Patients with known, clinically significant pericardial or pleural effusion
Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
Cardiac ejection fraction >= %, no evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings
Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than . cm at any location around the heart
Normal cardiac ejection fraction (greater than or equal to % by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within  weeks of the start of the treatment protocol
Patients with pre-existing interstitial lung disease (ILD), or pericardial/pleural effusion of grade  or higher; trace pericardial or pleural effusion is acceptable
Patients with evidence of a malignant pleural or pericardial effusion are excluded
Exclusion at the discretion of the principal investigator (PI) or delegate if participation to the study is deemed too risky (e.g. clinically significant pleural or pericardial effusion or ascites with possibly increased radio-toxicity)
Significant ascites or pericardial or pleural effusion
Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites
Presence of a small (or greater size) pericardial effusion
No history of the following:\r\n* Class III or IV congestive heart failure (CHF)\r\n* Pericardial effusion =<  months (grade  or )\r\n* Pericardial involvement with tumor\r\n* Grade  or higher pleural effusion =<  months
Cardiac ejection fraction of >= % as measured by resting echocardiogram, with no significant pericardial effusion
Presence of symptomatic pleural and/or pericardial effusion not appropriately treated
Presence of symptomatic pleural and/or pericardial effusion not appropriated treated
Normal cardiac ejection fraction and no evidence of pericardial effusion as determined by an echocardiogram
Concurrent medical condition which may increase the risk of toxicity, including:\r\n* Pleural or pericardial effusion of any grade
Patients with stage I or stage IV disease, including malignant pleural or pericardial effusion
Malignant pleural, pericardial, or peritoneal effusion if it is the only site of disease activity; i.e., if no other measurable tumor lesions exist
Prior history of pericarditis or pericardial effusion
Stage IV cancer according to TNM classification (th edition - UICC, December ; includes tumor with malignant pleural or pericardial effusion
Cardiac ejection fraction >%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant pleural effusion
Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than . cm at any location around the heart.
Uncontrolled pleural effusion, pericardial effusion, or ascites
Uncontrolled clinical symptoms including pleural effusion, pericardial effusion, or ascites, tumor-related pain, hypercalcemia (or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy)
Presence of a symptomatic moderate or large free-flowing pleural effusion on the basis of:\r\n* Chest radiograph: effusion filling >= / the hemithorax, OR\r\n* Computed tomography (CT)-scan: maximum anteroposterior (AP) depth of the effusion >= / of the AP dimension on the axial image superior to the hemidiaphragm, including atelectatic lung completely surrounded by effusion, OR\r\n* Ultrasound: effusion spanning at least three rib spaces with depth of  cm or greater in at least one interspace, while the patient sits upright
Uncontrolled pleural effusion, pericardial effusion, or ascites
Positive effusion cytology
Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
Malignant pleural effusion or pericardial effusion
Cardiac ejection fraction ? %, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings
Subjects with prior history of pericardial effusion or pleural effusion that required thoracentesis are excluded. Subjects with prior history of pericardial or pleural effusion that was clinically manageable and a maintained CMR for ?  year on a stable dose of dasatinib are allowed.
Significant pericardial effusion, pleural effusion, or ascites
